Clinical Observation Of Qishen Yiqi Dripping Pills On The Vulnerable Stage Of Heart Failure Patients With Qi Deficiency And Blood Stasis Syndrome

Purpose:By observing the effect of Qishen Yiqi Pills on the re-hospitalization rate,mortality and heart function of patients with qi deficiency and blood stasis syndrome heart failure during vulnerable period,provide basis for the application of traditional Chinese medicine in the vulnerable period of heart failure.Material and method:This study was a prospective randomized controlled study.A total of 66 patients with vulnerable heart failure who were discharged from the Department of Cardiology of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from June 2017 to October 2018 were enrolled in the group within 3 days after discharge.All of them met the diagnostic criteria for chronic heart failure and the syndrome differentiation criteria for TCM qi deficiency and blood stasis syndrome.The cases were divided into observation group and control group according to the principle of randomized control grouping,33 cases in each group.According to the relevant treatment guidelines and the indications,patients of both groups were treated with standardized treatment for chronic heart failure after discharge.The control group was only treated with western medicine.The observation group was given three times a day of oral administration of Qishen Yiqi Pills on the basis of Western medicine.The course of treatment is 3 months.Observe and compare the TCM syndrome scores,NYHA cardiac function grading,plasma NT-proBNP level,left ventricular ejection fraction(LVEF),left ventricular end diastolic diameter(LVEDD)before and after treatment and re-hospitalization rate and mortality due to heart failure during treatment.Evaluate the clinical efficacy of Qishen Yiqi Pills in the vulnerable period of heart failure,and analyze the data to determine its statistical significance.Results:1.There were no significant differences in age,sex,course of disease,heart rate,blood pressure,main causes of heart failure and NYHA cardiac function grading between the observation group and the control group(P > 0.05).2.After treatment,the TCM syndrome scores of the two groups were lower than those beforetreatment,and the observation group was superior to the control group(11.81±4.44 vs.16.42±6.64,P<0.01).The total effective rate of the observation group was higher than that of the control group(90.90).% vs.60.60%,P < 0.05),the difference was statistically significant.3.After treatment,the NYHA cardiac function grading of the two groups was improved,but there was no significant difference in the total effective rate between the two groups(87.88%vs.60.61%,P = 0.087).4.After treatment,the plasma NT-proBNP levels of the two groups decreased significantly,and the observation group was significantly better than the control group(459.47 +415.91 vs.642.00 +184.48,P < 0.01),the difference was statistically significant.5.After treatment,the LVEF of the two groups was significantly increased,and the observation group was significantly better than the control group(50.94(+8.68 vs.48.87(+3.52),P < 0.05).6.After treatment,LVEDD decreased in both groups,but there was no significant difference between the two groups(47.91 +7.91 vs.50.87 +6.98,P=0.120).7.Re-hospitalization rate was 3.03% in the observation group and 15.15% in the control group,with no significant difference(P=0.087);there was no significant difference in cardiogenic mortality between the two groups(3.03% vs.6.06%,P=0.555).Conclusion:On the basis of standardized treatment of chronic heart failure,Qishen Yiqi Pills can significantly improve the TCM syndromes,reduce plasma NT-proBNP level and improve LVEF in vulnerable period of heart failure patients with Qi deficiency and blood stasis syndrome,thereby improve the heart function of patients in vulnerable period.